KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Change in Receivables: 2016-2024

Historic Change in Receivables for Moderna (MRNA) over the last 9 years, with Dec 2024 value amounting to -$534.0 million.

  • Moderna's Change in Receivables fell 27.69% to $1.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$503.0 million, marking a year-over-year decrease of 66.56%. This contributed to the annual value of -$534.0 million for FY2024, which is 8.32% down from last year.
  • Per Moderna's latest filing, its Change in Receivables stood at -$534.0 million for FY2024, which was down 8.32% from -$493.0 million recorded in FY2023.
  • Over the past 5 years, Moderna's Change in Receivables peaked at $1.8 billion during FY2021, and registered a low of -$1.8 billion during FY2022.
  • Its 3-year average for Change in Receivables is -$939.0 million, with a median of -$534.0 million in 2024.
  • Its Change in Receivables has fluctuated over the past 5 years, first skyrocketed by 19,885.71% in 2020, then crashed by 200.34% in 2022.
  • Over the past 5 years, Moderna's Change in Receivables (Yearly) stood at $1.4 billion in 2020, then increased by 28.81% to $1.8 billion in 2021, then crashed by 200.34% to -$1.8 billion in 2022, then surged by 72.46% to -$493.0 million in 2023, then dropped by 8.32% to -$534.0 million in 2024.